Home

G. Walmsley Graham

CIK 1777517 · last filed 2026-06-23

G. Walmsley Graham is a corporate insider who has filed 38 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for OLMA, was dated Jun 23, 2026. Across all open-market trades the lifetime net is +$61.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $22.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$22.75M

Companies

3

Total Filings

38

Lifetime Open-Market Net

$60.96M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OLMA Director 1,800,000 $11.54 $20.76M -$15.45M 16 2026-06-23
Akero Therapeutics, Inc. (AKRO) Delisted Director 0 $54.65 $0 $56.36M 18 2025-12-09
ALXO Director 995,000 $2.00 $1.99M $20.05M 4 2021-06-15

Recent Filings

38 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 OLMA Grant (A) — $0 EDGAR
2025-12-09 Akero Therapeutics, Inc. (AKRO) Delisted Disp (D) −1,302,398 $0 EDGAR
2025-10-10 Akero Therapeutics, Inc. (AKRO) Delisted Exer (M) +90,832 $1.87M EDGAR
2025-06-13 OLMA Grant (A) — $0 EDGAR
2025-06-05 Akero Therapeutics, Inc. (AKRO) Delisted Grant (A) +9,398 $0 EDGAR
2025-05-13 OLMA — — $0 EDGAR
2025-03-27 Akero Therapeutics, Inc. (AKRO) Delisted Buy (P) +200,000 $8.79M EDGAR
2025-02-07 Akero Therapeutics, Inc. (AKRO) Delisted Buy (P) +200,000 $9.60M EDGAR
2024-12-18 OLMA Mixed — $0 EDGAR
2024-12-17 OLMA Mixed −1,401,522 -$9.46M EDGAR
Showing 1–10 of 38
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.